# Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

> **NCT00017069** · PHASE2 · TERMINATED · sponsor: **CTI BioPharma**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00017069
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-02
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** — (—)
- **Last updated:** 2020-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017069, "Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00017069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*